| HS Code | 182107 |
| Product Name | Vitamin B12 0.1% Pharma Grade API |
| Active Ingredient | Cyanocobalamin (Vitamin B12) |
| Concentration | 0.1% w/w (1 mg Vitamin B12 per gram) |
| Grade | Pharma Grade |
| Dosage Forms | Tablet, Capsule, Granule, Injection |
| Routes Of Administration | Oral and Injectable |
| Appearance | Red or pinkish crystalline powder or free-flowing granules |
| Solubility | Soluble in water; sparingly soluble in ethanol |
| Assay | 90.0% - 110.0% of labeled Vitamin B12 content |
| Heavy Metals | Complies with pharmacopoeial limits |
| Storage | Store in a cool, dry place in tightly closed containers, protected from light |
| Packaging | Conventionally sealed with desiccant and protected from oxidation |
As an accredited Vitamin B12 0.1% Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in 25 kg net fiber drums with double polythene lining, sealed for moisture protection. Suitable for pharmaceutical formulation use. |
| Container Loading (20′ FCL) | Loaded as 20′ FCL: palletized cartons/drums, stretch-wrapped, ventilated, dry, moisture-protected, segregated for pharma-grade Vitamin B12 0.1% API safety. |
| Shipping | Vitamin B12 0.1% Pharma Grade API ships in sealed, light-protected double polythene bags inside aluminum foil pouches, placed in sturdy fiber drums. Transport at ambient temperature, away from moisture and direct sunlight. Shipment complies with international pharmaceutical regulations, with full documentation and stability data for oral and injectable use. |
| Storage | Store in a cool, dry, well-ventilated area at controlled room temperature, preferably below 25°C. Protect from light, moisture, and oxygen in a tightly closed, opaque container. Avoid exposure to heat, direct sunlight, and incompatibles. Keep original packaging sealed until use, and follow applicable pharmaceutical storage regulations. |
| Shelf Life | Shelf life is typically 24–36 months when stored in airtight, light-resistant containers at controlled room temperature, away from moisture. |
The 0.1% pharmaceutical-grade cyanocobalamin material is handled as a 1,000 µg/g active trituration requiring geometric dilution before direct compression. A label claim of 100 µg cyanocobalamin per unit therefore requires 100 mg of the preblend. When the core weight is 400 mg, the preblend fraction is 25.0% w/w; when the core is reduced to 250 mg, the fraction rises to 40.0% w/w, at which point the excipient matrix, not the active material, governs flow and compressibility. Production-scale V-blenders operated at 60–70% gross volume and 20–30 rpm for 15–20 minutes are standard, but over-blending beyond 30 minutes can induce density-driven segregation because the preblend carrier is typically a fine-milled calcium phosphate or mannitol with D90 below 75 µm. Rotary tablet press behavior is characterized by turret speeds of 40–80 rpm and main compression forces between 8 kN and 18 kN for 9.5–12.0 mm round tooling; lower forces produce capping, while higher forces can reduce disintegration below 30 seconds in USP <701> if the disintegrant loading is insufficient. Compliance for this segment is anchored to the Cyanocobalamin Tablets USP monograph, with assay acceptance 90.0–110.0%, content uniformity acceptance value ≤ 15.0 under USP <905>, and disintegration under USP <701>. Residual elemental impurities follow ICH Q3D based on the final daily intake. Cleaning validation on shared tablet presses must demonstrate swab recovery below the permitted daily exposure; cyanocobalamin is detectable by HPLC with UV detection at 361 nm and retention time confirmation against USP reference standard. Terminal product types include cyanocobalamin monotherapy tablets at 25 µg, 100 µg, and 250 µg label claims, B-complex tablets, and two-piece hard gelatin or HPMC capsules. Capsule filling on a dosator-type machine with size 3 or 4 shells typically uses fill weights of 200–400 mg; a 100 mg preblend load per capsule creates a 25–50% w/w powder bed and requires moisture content below 2.0% after drying to prevent plug formation.
In high-shear wet granulation of sachet and dry syrup formulations, the 0.1% cyanocobalamin trituration is incorporated before binder addition to avoid localized over-wetting of the active carrier. A target of 50 µg per 2 g sachet requires 50 mg of the preblend, equivalent to 2.5% w/w of the fill mass; a 100 µg per 2 g sachet raises the load to 5.0% w/w. Dry syrup intended to deliver 250 µg per 5 mL after reconstitution to 100 mL incorporates 5 g of the preblend in a powder mass of 50 g, yielding 10.0% w/w. Oral granule compliance is evaluated under Ph. Eur. 2.9.5 for uniformity of mass of single-dose preparations and USP <905> when the product is labeled as a solid oral dosage form; loss on drying under USP <731> is held below 2.0% to prevent moisture-induced color shift in finished sachets. Wet granulation is carried out in a high-shear granulator with impeller tip speed 2–5 m/s and chopper speed 1,500–3,000 rpm; purified water or a 2–5% w/w povidone solution is sprayed at 0.5–1.0 L/h/kg dry mass until endpoint torque rises 20–30% above dry blend baseline. The wet mass is screened through a 1.5–2.0 mm mesh and dried in a fluid-bed dryer with inlet air 60–65°C and product temperature 35–40°C. Cyanocobalamin exposure to sustained wet mass temperatures above 45°C in acidic binder systems can initiate assay loss; production batches are therefore monitored with in-process HPLC rather than end-of-run composite sampling alone. Terminal product types include granulated single-dose sachets, dry syrup powders in amber HDPE bottles, and dispersible granules for reconstitution.
Prenatal multivitamin-mineral tablets typically carry cyanocobalamin label claims between 12 µg and 100 µg. The 0.1% preblend contributes 12 mg to 100 mg per unit, which in a 1,200–1,500 mg core equates to 0.8–8.3% w/w. The low mass fraction of the active preblend in a high mineral load creates a content uniformity risk that is not resolved by prolonged blending alone. Ferrous fumarate, cupric oxide, and calcium carbonate fractions can adsorb cyanocobalamin onto particle surfaces, and ascorbic acid-containing overlays accelerate photolytic and oxidative loss when direct contact occurs during storage. Formulation practice therefore separates the 0.1% trituration from redox-active minerals by binder granulation of the mineral phase, followed by final blending of the active preblend in a low-speed V-blender at 10–15 rpm for 10–15 minutes before compression. Compliance follows USP <905> for content uniformity with an acceptance value ≤ 15.0, USP <2040> for disintegration of dietary supplement tablets where applicable, and ICH Q3D for elemental impurities contributed by the mineral matrix. The prenatal formulation is typically tested for vitamin B12 stability under ICH Q1A; open-dish photostability studies demonstrate that unprotected cyanocobalamin exposed to 1.2 million lux hours visible light and 200 Wh/m² UV can degrade beyond 10%, forcing amber bottle or foil-foil blister packaging when the tablet contains iron or ascorbic acid. Compression of mineral-loaded prenatal tablets is performed on a rotary press with precompression force 5–10 kN and main compression 25–40 kN for oval tooling exceeding 17 mm length. The preblend is sieved through a 30-mesh screen and introduced last to protect the cyanocobalamin from extended shear contact with metal oxides. Tablet hardness is maintained at 100–180 N; hardness above 200 N can extend disintegration beyond 30 minutes due to high mineral content. Terminal product types are prenatal tablets, iron-folic acid-B12 caplets, and multivitamin-mineral tablets for maternal nutrition.
A 0.1% cyanocobalamin stock solution containing 1,000 µg/mL active drug is the metered active feed for oral liquid drops and syrups. Final dosing at 5 µg/mL is obtained by transferring 0.5 mL of stock per 100 mL of vehicle, corresponding to 0.5% v/v. The vehicle is prepared with purified water, sorbitol or sucrose, citric acid/sodium citrate buffer to pH 4.0–5.0, and a preservative system qualified under USP <51> antimicrobial effectiveness testing. Microbiological quality must meet Ph. Eur. 5.1.4 criteria for oral liquids; assay and degradation product limits follow USP <621> with peak purity verification at 361 nm. Processing is conducted in a nitrogen-purged stainless-steel compounding vessel because dissolved oxygen accelerates cyanocobalamin oxidation. The stock solution is filtered through a 0.45 µm cartridge before dilution, filled into amber glass bottles with child-resistant caps, and stored below 25°C. Terminal product types include pediatric oral drops delivering 25–50 µg per 0.5–1.0 mL and geriatric B12 syrups at 5–25 µg/mL. Published data for long-term stability of this specific sorbitol vehicle at elevated humidity is limited; moisture barrier packaging is therefore mandatory in climate zones III and IV.
When the 0.1% cyanocobalamin concentrate is used for aqueous injectable compounding, the active concentration is 1,000 µg/mL, which is the direct concentration of many cyanocobalamin injection monographs. For a 100 µg/mL final product, the concentrate is diluted 1:10 with normal saline or bacteriostatic water, corresponding to 10.0% v/v concentrate. The compounded solution is buffered to pH 4.5–5.0 with acetate or citrate because cyanocobalamin stability decreases rapidly at alkaline pH and in the presence of reducing agents. Dissolved oxygen in the headspace is displaced with nitrogen, and the line fill volume is set with an overage of 5–10% to compensate for terminal sterilization loss. Sterility is validated under USP <71> with a minimum 14-day incubation; bacterial endotoxin is tested under USP <85> using the calculated limit based on maximum dose and the K/M formula. Particulate matter is controlled under USP <788> and visible particulates under USP <790>. Filtration uses a 0.22 µm PVDF or PES membrane, and the filling line operates under ISO 14644-1 Class 7 background with Class 5 local protection for open aseptic manipulations. Terminal sterilization in a steam autoclave at 121°C for 15 minutes can produce assay loss of 5–8% if headspace oxygen is not fully removed; therefore the overage is set from in-house thermal stability data. Production-scale rotary ampoule lines typically run at 3,000–8,000 units/hour; residual oxygen in the headspace must be below 2.0% v/v before sealing to keep the assay within the approved specification after terminal sterilization. Batch-to-batch variance in pH buffering capacity has been observed when the acetate buffer is added before complete dissolution of the concentrate; in-process pH is therefore recorded after 10 minutes of recirculation and adjusted before filtration. Terminal product types are single-dose amber glass ampoules and vials at 100 µg/mL and 1,000 µg/mL, as well as multi-dose vials where a validated preservative such as 1.0% w/v benzyl alcohol is included according to 21 CFR 210.3.
Compounding cyanocobalamin into parenteral nutrition admixtures requires electrolyte and trace element sequencing that differs from standard vitamin addition protocols. The 0.1% stock is first diluted to a 10 µg/mL working solution by adding 1 mL of stock to 99 mL of preservative-free saline; then 1 mL of this working solution is added per 1,000 mL admixture to deliver 10 µg of cyanocobalamin per bag. This dilution approach avoids syringe measurement errors associated with transferring volumes below 0.05 mL. The addition sequence must avoid direct contact between cyanocobalamin and ascorbic acid or trace element concentrates containing copper and selenium, because rapid electron transfer can occur at pH values above 6.0. The admixture is prepared under USP <797> aseptic conditions, and microbial risk is controlled by terminal 0.22 µm filtration of the working solution before transfer. Light exposure during compounding and infusion is minimized by amber or opaque overwrap; cyanocobalamin can undergo photodegradation in the presence of riboflavin at levels above 2 mg per bag. Terminal product types are hospital-compounded total parenteral nutrition bags, infusion syringes, and ambulatory infusion cassettes. Published data for this specific multi-electrolyte configuration is limited, so end-user stability studies are required beyond 24 hours under refrigeration.
Competitive Vitamin B12 0.1% Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Vitamin B12 0.1% Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a low-strength cyanocobalamin trituration in which the nominal active content is 0.1% w/w, equivalent to 1.0 mg/g on an as-is basis. This product form is used when unit doses are in the microgram-to-low-milligram range and direct weighing of pure crystalline cyanocobalamin would introduce unacceptable relative standard deviations in dosage-unit weight. The active entity is cyanocobalamin, C63H88CoN14O14P, with a molecular weight of approximately 1355.37 g/mol. The remaining mass is a manufacturer-specified pharma-grade carrier, typically a free-flowing diluent such as mannitol, dicalcium phosphate, or microcrystalline cellulose for oral solid forms, or a parenteral-suitable soluble carrier where the grade is intended for injectable compounding after dissolution. Model designations generally encode the carrier identity, nominal particle-size target, and monograph status; because no single compendial monograph covers all possible 0.1% trituration compositions, each supplier’s specification must be verified against the intended dosage-form process.
Uniformity of dosage units is governed by USP <905> for solid oral forms; a passing acceptance value of ≤15.0 is required for tablets and capsules. A 0.1% premix is used to place the active ingredient mass inside a weighable matrix. For a 100 µg vitamin B12 dose, pure API weighing would require 0.1 mg per unit; a 0.1% trituration raises the dispensed mass to 100 mg, which typical tablet presses and encapsulation machines can handle with relative standard deviations below 2%. The premix must be homogeneity-tested by stratified sampling of the blend across blender discharge, hopper, and final dosage units; acceptance values should be aligned with current approved applications and compendial blend uniformity guidance. For parenteral use, the 0.1% form is used to prepare a bulk solution rather than to ensure solid dosage uniformity, so the critical parameters shift to solubility, pyrogen burden, and particulate matter.
For direct compression lines with rotary tablet presses operating at turret speeds between 30 rpm and 80 rpm, the low-dose cobalamin component is usually introduced by geometric dilution: a portion of the carrier is preblended with the 0.1% premix, passed through a 600 µm sieve, and then added to the main blender. Segregation potential is a function of the particle-size difference between the trituration carrier and the main excipient. If the premix uses a fine-milled mannitol with a D50 near 60 µm and the primary diluent has a D50 above 180 µm, hopper discharge can stratify the active component. In such cases, a pre-blend step with 10–20% of the total bulking agent is used, unless the formulation is validated under a specific blender speed and mixing time. The product’s 0.1% concentration is not low enough to behave as a trace component requiring absolutely dust-free handling, but it remains high enough that feeder over-dosing will produce a batch-level assay outside the ±5.0% release limit where such a filed limit applies.
Tablet press feeder speed and die fill require particular attention when the 0.1% premix is based on dicalcium phosphate dihydrate. The premix should be screened through a 500–850 µm mesh before use to break soft agglomerates; oversized material retained on the sieve indicates moisture ingress or carrier compaction. For formulations compressed on high-speed rotary presses with precompression force below 5 kN and main compression force between 8 kN and 25 kN, the friability should be measured according to USP <1216>. The low active content does not generally influence compactability, but the carrier fraction can shift ejection force and tablet hardness; therefore, the premix carrier is treated as a functional component in the same way as the primary filler rather than as a minor additive.
The raw-material specification for a 0.1% cyanocobalamin trituration includes assay, content uniformity of the premix, loss on drying, residual solvents, elemental impurities, particle-size distribution, and microbial limits. Because the active entity is present at low potency, the assay range should be established from the supplier’s analytical capability and the applicant’s formulation tolerance; a release window of 0.090–0.110% w/w is often applied unless a tighter limit is justified by clinical dose requirements. The carrier must be identified and quantified where it affects dissolution or parenteral acceptability. Batch-to-batch particle-size control is more important for solid oral processes than for parenteral dissolution; a D90 exceeding the primary filler D90 by a factor of 3 may lead to localized superpotent zones in the final blend.
| Parameter | Typical acceptance criterion | Method / reference |
|---|---|---|
| Assay (cyanocobalamin) | 0.090–0.110% w/w as-is | HPLC-UV at 361 nm |
| Loss on drying | ≤5.0% w/w | USP <731> |
| Total aerobic microbial count | ≤10^3 CFU/g | USP <61> |
| Total yeast and mould count | ≤10^2 CFU/g | USP <61> |
| Bacterial endotoxins, parenteral grade only | Derived from dose and route per USP <85> | USP <85> |
Capsule filling on dosator-based machines requires the blend to remain sufficiently cohesive for slug formation while still releasing cleanly from the dosator tip. The addition of a 0.1% B12 trituration can alter powder rheology if the carrier is hygroscopic or if the premix is poorly deagglomerated. Operating parameters such as dosator height, compression thickness, and turret speed are adjusted when the premix concentration changes from 0.1% to 1.0% because the carrier mass contributes to plug density. The target fill weight for a 100 µg dose is 100 mg of premix, but formulation loss due to fines or agglomerates should be verified by in-process fill weight checks and content uniformity testing at start-up, mid-run, and end-run. For granule products, the premix may be added before wet granulation, sprayed as a dispersion, or adhered to granules by dry blending; each route changes the contact time between cobalamin and water, which is relevant because cyanocobalamin degrades under light and in the presence of certain reducing agents.
Granule-based oral powders intended for sachet or spoon administration are usually manufactured by blending the 0.1% premix after dry granulation to protect the active entity from direct moisture contact during granulation. If the premix is included before wet granulation, the granulation fluid must be checked for compatibility with the carrier; mannitol recrystallizes at certain moisture levels, and dicalcium phosphate dihydrate can lose water of crystallization above 40°C. Granule particle-size specifications, such as retention on a 180 µm sieve and fines below 15% w/w through a 75 µm sieve, are established during development to ensure uniform dosing from the final container. The 0.1% nominal content, combined with granule size distribution, directly affects unit-dose accuracy when the consumer or pharmacist doses by volume rather than by weight.
The critical operational difference is the mass of carrier introduced with the active ingredient. For a 1 mg dose, the 0.1% premix contributes 1 g of carrier per dose, whereas a 1.0% trituration contributes 100 mg and pure cyanocobalamin contributes 1 mg. This affects direct compression blend bulk density, disintegration time, and the maximum tablet size. In injectable compounding, a 0.1% premix with an insoluble oral-grade carrier is unsuitable; the parenteral grade must dissolve completely in the intended aqueous vehicle and pass sterile filtration. Differences from alternative cobalamin entities also matter: methylcobalamin, hydroxocobalamin, and cyanocobalamin are not interchangeable on an equal-mass basis because their molecular weights and labelled clinical indications differ. The 0.1% cyanocobalamin premix is typically the most stable solid oral candidate among the cobalamin forms, but purity and ligand-shift stability should be confirmed under the specific formulation pH.
| Product form | Nominal active content | Mass required for 100 µg dose | Main operational constraint |
|---|---|---|---|
| 0.1% cyanocobalamin premix | 0.1% w/w | 100 mg | Carrier mass and blend uniformity |
| 1.0% cyanocobalamin trituration | 1.0% w/w | 10 mg | Low fill mass and segregation risk |
| Pure crystalline cyanocobalamin | Compendial assay, typically 97.0–102.0% | 0.1 mg | Analytical weighing error; geometric dilution required |
For injectable-grade processing, a 0.1% cyanocobalamin API is dissolved and then sterile-filtered or heat-sterilized according to the thermal stability limits of cobalamin. The solution should be prepared in a light-resistant vessel, because photolysis accelerates loss of cyanocobalamin activity; amber glass or an opaque stainless-steel line is used from dissolution through filling. The parenteral form falls under USP <1> Injections, USP <85> Bacterial Endotoxins, and USP <788> Particulate Matter in Injections for subvisible particles. If the premix contains a carrier intended only for oral solids, the resulting solution will fail the particulate or solubility requirements; therefore the “Oral & Injectable” designation requires confirmation that the particular lot is the parenteral-suitable grade. Finished injectable solutions are typically filtered through a 0.22 µm membrane, and the holding time between dissolution and filtration is limited because cobalamin can be adsorbed onto certain filter materials and metal surfaces if the solution is held for extended periods.
Solid oral products containing the 0.1% premix are tested for dissolution as part of release and stability, using compendial apparatus appropriate to the dosage form. For immediate-release tablets and capsules, USP <711> Dissolution is applied with a product-specific medium, volume, and agitation speed; typical development workflows screen media at 50 rpm or 75 rpm using 900 mL of dilute acid or water. The dissolution profile is more sensitive to the carrier than to the low active percentage, because the carrier can either accelerate dispersion through water-soluble channels or retard disintegration if it forms a viscous layer. Analytical quantification at the low concentration generated by a 100 µg dose requires a validated HPLC-UV method with sufficient sensitivity; typical signal-to-noise requirements are maintained by selecting the cyanocobalamin detection wavelength near 361 nm and using a narrow-specification column to separate related cobalamins.
If the premix is incorporated into a wet granulation fluid, the binder solution must be protected from prolonged exposure to ambient light and high pH. Cyanocobalamin stability is pH-dependent; strongly acidic or alkaline granulation fluids can promote ligand exchange or degradation. A granulation endpoint at moisture content 3–5% w/w after drying is typical for low-dose cobalamin granules, but the exact drying temperature should not exceed the thermal limit established for the selected carrier and active entity. Drying at temperatures above 60°C may accelerate degradation if residual moisture and light exposure remain uncontrolled; some manufacturers specify a drying temperature of 40–50°C for cobalamin-containing granulates. The 0.1% premix should not be combined with strong reducing agents such as ascorbic acid in the same wet phase without confirmatory stability data, because cyanocobalamin can be reduced to less active cobalamin species. Published data for this specific configuration is limited; therefore, forced degradation studies under the intended granulation pH and drying protocol are required. Batch-scale validation should include assay and related substances at granule discharge, after drying, and after final blend compression to verify that the process does not shift the 0.1% nominal potency.
The API is stored in a light-resistant, tightly closed container at controlled room temperature, unless the manufacturer’s stability data support alternative conditions. Storage with the product in direct contact with strong oxidizers or reducing agents is avoided; the container closure system should be qualified for moisture vapor transmission if the oral-grade carrier is hygroscopic. In global distribution, the product falls under the pharmaceutical quality system expectations of 21 CFR 211.80 and Part 211 component controls where applicable, and under ICH Q3C for residual solvents and ICH Q3D for elemental impurities. Confirmation of the carrier identity and its acceptance for the intended route—oral or injectable—is required before batch release, because the nominal 0.1% content alone does not define the product’s regulatory suitability for every dosage form.
